Trial · NCT03458325
Results by group121
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 121
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Healthcare Utilization Costs | Furoscix Infusor Prospective Treatment | HF-related healthcare costs | 2920.30 | Standard Deviation 7073.20 | US Dollars |
| Healthcare Utilization Costs | Furoscix Infusor Prospective Treatment | Overall healthcare costs | 7512.30 | Standard Deviation 11,905.50 | US Dollars |
| Heart-Failure Related Hospital Admissions | Furoscix Infusor Prospective Treatment | 1 | Participants | ||
| All-Cause Hospital Admissions | Furoscix Infusor Prospective Treatment | 6 | Participants | ||
| Heart-Failure Related Emergency Department Visits | Furoscix Infusor Prospective Treatment | 1 | Participants | ||
| Heart-Failure Related Emergency Department Visits | Matched Historical Control | 4 | Participants | ||
| Heart-Failure Related Clinic Visits | Furoscix Infusor Prospective Treatment | 24 | Participants | ||
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Baseline | Summary Score | 29.9 | Standard Deviation 22.8 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Day 30 | Summary Score | 42.8 | Standard Deviation 28.4 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Baseline | Physical Limitation Score | 37.1 | Standard Deviation 30.1 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Day 30 | Physical Limitation Score | 43.7 | Standard Deviation 32.0 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Baseline | Symptom Frequency Score | 33.1 | Standard Deviation 28.6 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Day 30 | Symptom Frequency Score | 50.5 | Standard Deviation 32.3 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Baseline | Quality of Life Score | 27.1 | Standard Deviation 28.0 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Day 30 | Quality of Life Score | 35.9 | Standard Deviation 29.8 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Baseline | Social Limitation Score | 29.0 | Standard Deviation 26.1 | score on a scale |
| KCCQ-12 Scores | Furoscix Infusor Prospective Treatment - Day 30 | Social Limitation Score | 40.9 | Standard Deviation 31.3 | score on a scale |
| Mean Change in NT-proBNP and BNP | Furoscix Infusor Prospective Treatment - Baseline | NT-proBNP | 823.4 | Standard Deviation 1043.9 | pg/ml |
| Mean Change in NT-proBNP and BNP | Furoscix Infusor Prospective Treatment - Day 30 | NT-proBNP | 700.7 | Standard Deviation 896.2 | pg/ml |
| Mean Change in NT-proBNP and BNP | Furoscix Infusor Prospective Treatment - Baseline | BNP | 785.1 | Standard Deviation 1129.9 | pg/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03458325/results